# Madrigal Pharmaceuticals (MDGL) – Educational Initiation of Coverage

This document is for educational and portfolio purposes only and does not constitute investment advice or a research recommendation.

## 1. Front stub
- Conceptual rating (Buy/Hold/Sell) for teaching purposes only:
- Conceptual target price and implied upside/downside:
- Key stats (ticker, price/date, market cap, net cash, EV, short interest):

## 2. Investment summary
- Core thesis bullet 1:
- Core thesis bullet 2:
- Key upside driver:
- Key risk:
- Additional watch item:

## 3. Company overview
### 3.1 Company history
- Timeline placeholders.

### 3.2 Strategy and focus
- Therapeutic focus, clinical priorities, commercial build.

### 3.3 Management and governance
- Key executives, board composition, incentives.

### 3.4 Financial position and cash runway
- Cash/investments, burn, financing history.

## 4. Pipeline overview
- Insert pipeline table/figure reference (e.g., from `figures/`).
- Brief bullets per asset status.

## 5. Resmetirom (Rezdiffra) in MASH
### 5.1 Mechanism of action and biology
- THR-β agonism overview.

### 5.2 MAESTRO clinical program overview
- Trial list summary.

### 5.3 Pivotal MAESTRO NASH results
- Key efficacy tables.

### 5.4 Outcomes and long-term safety studies
- MAESTRO Outcomes/NAFLD-1 follow-up.

### 5.5 Regulatory status and label
- FDA label summary, EMA outlook.

## 6. Market opportunity and competitive landscape
### 6.1 Epidemiology and addressable market
- Link to analysis outputs.

### 6.2 Current treatment paradigm
- Standard of care, off-label usage, GLP-1 penetration.

### 6.3 Competitive landscape (including GLP-1 based approaches)
- Key competitors snapshot.

### 6.4 Positioning of Rezdiffra
- Differentiation narrative.

## 7. Valuation
### 7.1 rNPV framework and key assumptions
- Reference model inputs.

### 7.2 Scenario analysis (bear/base/bull)
- Table placeholder.

### 7.3 Sensitivity analysis
- Tornado/sensitivity notes.

## 8. Catalysts
- Table fields: Date/Timing | Event | Type (clinical/regulatory/commercial/financial) | Directional impact.

## 9. Risks
### 9.1 Clinical and regulatory risks
- Trial design, endpoints, safety.

### 9.2 Commercial and competitive risks
- Uptake, payer behavior, GLP-1 headwinds.

### 9.3 Financial and execution risks
- Cash needs, supply chain, scaling.

## 10. Appendix
- Detailed MAESTRO trial tables.
- Additional competitive comparisons.
- Model assumption grids and supporting charts.
